Chancenoptimierung durch individualisierte ... - Tumorzentrum

More documents

Recommendations

Info

STREAM: phase II trial in metastatic uveal melanoma –Sorafenib 1 st line A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in patients with Chemonaïve Metastatic Uveal Melanoma (Sorafenib Treatment of Metastatic Uveal Melanoma) (EudraCT-No.: 2010- 022687-12) Start 02/2011 2 months “Run-in” Sorafenib PR, CR E V A L U A T E Stable R A N D O M I Z E Placebo 2x2 tablets Sorafenib 400 mg bid PR, CR, stable Continue Sorafenib Continue until PD or unacceptable tolerability PD Off-Study 32 2
Therapieoptionen des Uvea Melanoms Adjuvant DC Vaccination trial In High Risk Monosomy 3 Uveal melanoma STREAM trial Sorafenib 1st line therapy in stage IV Uveal melanoma Weltweit einmaliges Zentrum zur Systemtherapie von Uvea Melanomen
Page 1 and 2: Melanom 2012: Chancenoptimierung du
Page 3 and 4: Systemtherapie des Melanoms bis 201
Page 7 and 8: Targeted Therapy - Inhibitoren Boss
Page 9 and 10: Kinaseinhibitor PLX4032 (Vemurafeni
Page 11 and 12: BRAF + Tumorlast +++ Dynamik +++ Ki
Page 13 and 14: Systemtherapie im Stadium IV Melano
Page 15 and 16: Systemtherapie im Stadium IV Melano
Page 17 and 18: Wirkmechanismus von Ipilimumab Die
Page 19 and 20: ASCO 2010 - Immuntherapie 19
Page 21 and 22: Case history details • MRT showin
Page 23 and 24: Case history details • Melanoma S
Page 25 and 26: DNCB / DTIC Immunchemotherapie CR 7
Page 27 and 28: Systemtherapie Stadium IV Melanom B
Page 29 and 30: Targeted Therapy: Sorafenib 12.01.2
Page 31: MM Stadium IV: Therapieoptionen fü
Page 35: Melanom: Prognostische Faktoren 35
Page 38 and 39: Individualisierte Melanomtherapie G
Page 42 and 43: Melanom - Zukunft Protein und RNA A
Page 44 and 45: Dank - dem GMP Team B. Schuler-Thur
Page 46 and 47: Dank - allen Mitarbeitern der MM Am

Chancenoptimierung durch individualisierte ... - Tumorzentrum

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?